Computational identification of microRNAs and their targets in liver cirrhosis

HONGBO DU1*, HAO YU2*, YUYING YANG2, YUANYUAN SONG2, FEI WANG2, SHANGHENG LI2 and YUYONG JIANG2

1Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007; 2Department of Integrated Traditional and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P.R. China

Received November 2, 2015; Accepted April 21, 2017

DOI: 10.3892/ol.2017.7252

Correspondence to: Ms. Yuyong Jiang, Department of Integrated Traditional and Western Medicine, Beijing Ditan Hospital, Capital Medical University, 8 Jingshun Dongjie, Beijing 100015, P.R. China E-mail: yuyong_jiang@sina.com

*Contributed equally

Key words: liver cirrhosis, mRNA expression, microRNA expression, microRNA-target genes

Abstract. Previous studies have revealed that the deregulation of circulating miRNAs is associated with liver cirrhosis. The present study aimed to identify reliable candidate biomarkers to improve the early detection of liver cirrhosis. An integrated analysis of expression profiles of microRNAs (miRNAs/miRs) and mRNAs in liver cirrhosis tissues from the GEO database was performed. Next, the regulatory targets of the differentially expressed miRNAs in liver cirrhosis tissues were predicted. In addition, a regulatory network of miRNA-target genes was constructed. A total of 4 eligible mRNA expression profiling studies and 2 miRNA expression profiling studies met the inclusion criteria, and were thus included. A total of 48 differentially expressed miRNAs and 1,773 differentially expressed genes were identified in liver cirrhosis tissues compared with normal tissues. There were 240 miRNA-target pairs whose expression was negatively correlated. In the miRNA-target regulatory network, overexpression of miR-21 and miR-199a-3p was suggested to be closely associated with the progression of liver cirrhosis. In addition, functional enrichment analysis of the target genes indicated that cell cycle was the most significantly enriched pathway, and the dysregulation of leukemia inhibitory factor, cancerous inhibitor of protein phosphatase 2A and retinoblastoma-associated protein 1 clearly suggested their importance in the development of liver cirrhosis. We hypothesized that miR-21 and miR-199a-3p may be promising non-invasive diagnostic biomarkers for the early diagnosis of liver cirrhosis. The miRNA-target regulatory network may provide additional insight into the current data regarding the role of miRNAs in liver cirrhosis.

Introduction

Liver cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous connective tissue in response to chronic liver disease (1). Generally, liver cirrhosis is asymptomatic and unsuspected. Liver biopsy is considered as the gold standard for diagnosis of cirrhosis, followed by assessment of risk progression according to sequential histological grading of inflammation and staging of fibrosis. However, biopsy is prone to considerable sampling variability in all liver diseases (2‑5). Considering the limitations of liver biopsy, developing a reliable non-invasive and convenient method for liver cirrhosis has become an urgent requirement for early diagnosis (6‑8).

MicroRNAs (miRNAs/miRs) are a class of evolutionarily conserved small (18‑24 nucleotides) single‑stranded non-coding RNAs, which regulate target gene expression at the post-transcriptional level by the degradation of target mRNA or the suppression of mRNA translation subsequent to its specific binding to target mRNA (9,10). Dysregulated miRNA expression has been reported in nearly all types of human cancer, including hepatocellular carcinoma (HCC) (13‑15). Several miRNAs were identified as potential biomarkers for liver injury (16‑20). A previous study also identified frequent and extensive dysregulation of miRNA in liver adenoma and cirrhosis, and found that different liver cancer stages may affect the dysregulation of miRNA expression (21).

Expression microarray and next-generation sequencing may reveal more differentially regulated miRNAs. However, due to the heterogeneity of the disease, variations of sample sources and diversity of analysis methods, the results of these studies are inconsistent (13). In the present study, the miRNA and mRNA expression profiles for liver cirrhosis tissues from the Gene Expression Omnibus (GEO) database were integrated. In addition, differentially expressed mRNA target genes were predicted, and a miRNA-target regulatory network was constructed. Certain key miRNAs were established...
as biomarkers for diagnosis, prognosis and prediction of therapeutic response.

Materials and methods

Gene expression profiles. The miRNA and mRNA expression profiles for liver cirrhosis tissues were obtained from the public repository of GEO database (http://www.ncbi.nlm.nih.gov/geo) (22). The following key words were used: ‘Liver cirrhosis’ and ‘Homo sapiens’. Previous studies that compared gene expression profiling between liver cirrhosis and normal tissues or cultured cells were included in the present study. The type of study was defined as ‘expression profiling by array’ or ‘non-coding RNA profiling by array’.

Screening of differentially expressed miRNAs and mRNAs. Raw data were preprocessed via background correction and normalization. The Limma package in R (23) was used to identify the differentially expressed miRNAs and mRNAs between liver cirrhosis tissues and controls with an unpaired t-test, then a P-value was calculated. P-values from multiple studies were combined using Fisher’s exact test, and the random effects model was used to combine effect size from multiple studies. The miRNAs and mRNAs with a false discovery rate of <0.01 were regarded as differently expressed miRNAs and mRNAs.

Identification of regulatory targets for differently expressed miRNA. As the miRNAs recognize their regulatory targets through base pairing, computational methods have been invaluable for identifying these targets. The target genes for human miRNAs were downloaded from miRTarBase (http://miRTarBase.mbc.nctu.edu.tw), and the transcriptional targets of the identified miRNAs in liver cirrhosis tissues were predicted. In the present study, the differentially expressed target genes whose expression was inversely correlated with that of miRNAs were subjected to subsequent study. The miRNA-target gene interaction network in liver cirrhosis tissues was then constructed, and the network was visualized using Cytoscape (http://www.cytoscape.org) (24).

Functional enrichment analysis of differentially expressed target genes. The Database for Annotation, Visualization and Integrated Discovery (25) is the most common tool to analyze the functional enrichment of genes. To gain insights into the biological functions of miRNA target genes, Gene Ontology (GO) (26) classification and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (27) enrichment analysis were performed. P<0.05 was selected as the cutoff criterion.

Clinical specimens. The blood samples were obtained from 5 patients with liver cirrhosis and 3 healthy volunteers. Written consent was obtained from all of the study participants, and the project was approved by the committee of Ditan Hospital (Beijing, China) for the screening, inspection and data collection from the patients.

RNA preparation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted using the RNAiso Plus reagent (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol. Total RNA (1 µg) was reverse-transcribed using a cDNA Synthesis kit (Beijing Transgen Biotech Co., Ltd., Beijing, China), and the resulting cDNA was used as the template for qPCR. qPCR was performed in a BIO-RAD IQ5 Real-Time PCR system with a PCR SYBR Green Master mix reagent kit (Beijing Transgen Biotech Co., Ltd.). Following an initial denaturing for 2 min at 94˚C, qPCR was performed with 45 cycles of 94˚C for 20 sec and 60˚C for 34 sec. All reactions were performed in triplicate. The results were analyzed using the Cq method, using Data Assist Software version 3.0 (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The human β-actin gene was used as an endogenous control. The sequences of the PCR primers used are provided in Table I. The universal primer used for miR-21, miR-199a-3p and U6 was obtained from the miRcute Plus miRNA qPCR Detection kit (SYBR-Green) (cat. no. FP411; Tiangen Biotech Co., Ltd.). Data were analyzed with a one-way analysis of variance and Tukey's test using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Differentially expressed miRNAs and mRNAs in liver cirrhosis tissues. In total, 4 mRNA expression profiling studies and 2 miRNA expression profiling studies that met the inclusion criteria were included. The characteristics of each study are summarized in Table II. Of these studies, 166 cases of liver cirrhosis and 64 controls were analyzed.

Following normalization of the original miRNA and mRNA expression datasets, a total of 48 differentially expressed miRNAs were identified, including 5 that were upregulated and 43 that were downregulated (Table III). Using integrated analysis, a set of 1,773 differentially expressed genes (DEGs) were identified in liver cirrhosis tissues compared with normal tissues, including 1,037 upregulated and 736 downregulated genes.

Regulatory network of miRNAs and targets in liver cirrhosis. The miRTarBase database was used to predict the putative transcriptional targets of upregulated or downregulated miRNAs in liver cirrhosis tissues. Subsequent to comparing the putative targets with DEGs in liver cirrhosis tissues, a total of 240 miRNA-target gene pairs, whose expression was inversely correlated, were obtained. According to the miRNA-target gene pairs, a miRNA-target gene regulatory network was constructed (Fig. 1). In the network, the top three miRNAs (miR-21, miR-18a and miR-375) regulated the majority of the target genes. Leukemia inhibitory factor (LIFR) was identified as a target of miR-21, whereas cancerous inhibitor of protein phosphatase 2A (KIAA1524) and E2F transcription factor 1 (E2F1) were identified as targets of miR-181b.

Functional enrichment analysis. GO enrichment analysis of all target genes was performed to understand their biological functions. It was identified that the significantly enriched GO terms for molecular functions were protein binding, nucleotide binding and DNA binding. The significantly enriched GO
terms for cellular components were nucleus, cytoplasm and cytosol, while those for biological processes were mitotic cell cycle, cell division and DNA replication (Table IV).

The results of KEGG pathway enrichment analysis indicated that the most significantly enriched pathway was the cell cycle, which may have a significant effect on liver cirrhosis (Table V).

**RT-qPCR validation.** To validate the associated between miRNAs and their target genes in the regulatory network, the blood samples from 5 pairs of patients with liver cirrhosis and normal controls were used. hsa-miR-21 (P=0.1678), hsa-miR-199a-3p (P=0.0001) and KIAA1524 (P=0.0028) were selected for RT-qPCR. The RT-qPCR results indicated that the expression was consistent with the integrated analysis data (Fig. 2).

**Discussion**

An increasing number of studies have focused on the role of miRNAs in regulating cancer progression and metastasis, including proliferation, invasion, migration, angiogenesis and apoptosis (28,29). Emerging evidence suggests that circulating miRNAs may function as stable, reliable and non-invasive diagnostic biomarkers for cancer (30). In the present study, 2 miRNA expression profiling studies and 4 mRNA expression profiling studies of liver cirrhosis tissues were integrated, and a set of 48 differentially expressed miRNA and 1,773 DEGs were identified. By bioinformatics prediction, a total of 240 miRNA-target gene pairs were obtained, whose expression was inversely correlated. The miRNA-targets regulatory network was constructed for liver cirrhosis tissues. In the miRNA-targets regulatory network, it was identified that the top ten upregulated and downregulated miRNAs were hsa-miR-212, hsa-miR-21, hsa-miR-199a-3p, hsa-miR-142-5p, hsa-miR-142-3p, hsa-miR-132, hsa-miR-139-5p, hsa-miR-181b, hsa-miR-21* and hsa-miR-18a, and the majority of them had previously been identified to be closely associated with alcoholic liver.
Several miRNAs are involved in hepatic fibrogenesis (20,35,36). It was previously suggested that miR-21 was upregulated at the onset of fibrosis in the human liver, and that it may promote fibrogenic activation of fibroblasts (37,38) and be involved in the amplification of certain important cellular signaling pathways (39,40). A recent study also indicated that a significant elevation of hepatic miR-21 expression is associated with mitogen-activated protein kinase 3 signaling and epithelial-mesenchymal transition in liver fibrosis (34). The miR-199 family is associated with liver fibrosis. By comprehensive analysis, Murakami et al (41) identified that the high expression of 4 miRNAs (miR-199a, miR-199a\(^{-}\), miR-200a and miR-200b) were closely associated with the progression of liver fibrosis in humans and mice. Consistent with this, the present study revealed that miR-21 and miR-199a-3p were also significantly upregulated in liver cirrhosis tissues, implying that they may serve an important role in the progression of liver cirrhosis and that they may be promising biomarkers for the early diagnosis of liver cirrhosis.

A previous study demonstrated that the other two miRNAs, miR-142-3p and miR-142-5p, were significantly downregulated in HCC, and that they may cooperatively regulate cell movement (42). Conversely, the results of the present study indicated that miR-142-5p and miR-142-3p were significantly upregulated in liver cirrhosis tissues compared with normal tissues, implying that the expression pattern of these 2 miRNAs may be particular to liver cirrhosis, and that they may serve different roles in liver cirrhosis and HCC by a currently unknown mechanism.

In addition, Wang et al (43) identified that the expression of miR-181b may be induced by transforming growth factor-β1, which serves an important role in liver cirrhosis. miR-132 expression may be induced following alcohol intake, and it was previously shown to be increased in alcoholic liver disease (31). It was indicated that serum miR-18a was significantly higher in patients infected with hepatitis B virus (HBV) with HCC compared with healthy controls, and it may be used in discriminating HBV-associated HCC from chronic hepatitis or cirrhosis (32). Notably, in the present study, the aforementioned 3 miRNAs (miR-181b, miR-132 and miR-18a) were significantly downregulated in liver cirrhosis tissues compared with normal tissues, indicating that they may exhibit potential for diagnostic and therapeutic applications in liver cirrhosis.

In order to additionally investigate the role of miRNAs in liver cirrhosis, the transcriptional targets of the identified miRNAs in liver cirrhosis tissues were predicted, and several targets were noted, including LIFR, KIAA1524 and E2F1. It was observed that the LIFR\(β\) subunit is intensely expressed in reactive bile duct ductules in the cirrhotic liver, in which bile duct proliferation occurs frequently (44). Previous studies have demonstrated that KIAA1524 is a cellular inhibitor of protein phosphatase 2A, which is an important tumor-suppressor protein, and that the inhibition of KIAA1524 may determine the apoptotic effects of erlotinib on HCC cells (45-47). An additional important target was E2F1, which is considered a novel fibrogenic gene, and was identified to be highly upregulated in human liver cirrhotic specimens (48).

### Table III. List of differentially expressed miRNAs in liver cirrhosis.

| miRNAs         | Log (fold-change) | P-value   |
|----------------|------------------|-----------|
| **Upregulated miRNAs** |                  |           |
| hsa-miR-212     | 4.45E-01         | 6.29x10^{-4} |
| hsa-miR-142-5p  | 9.23E-01         | 1.88x10^{-3} |
| hsa-miR-142-3p  | 9.39E-01         | 2.38x10^{-3} |
| hsa-miR-199a-3p | 1.07E+00         | 8.38x10^{-4} |
| hsa-miR-21      | 1.09E+00         | 4.15x10^{-4} |
| **Downregulated miRNAs** |                |           |
| hsa-miR-132     | -9.37E-01        | 7.20x10^{-4} |
| hsa-miR-139-5p  | -9.18E-01        | 4.80x10^{-4} |
| hsa-miR-181b    | -8.57E-01        | 2.22x10^{-4} |
| hsa-miR-21\(^{-}\) | -8.36E-01        | 3.55x10^{-4} |
| hsa-miR-18a     | -8.31E-01        | 4.50x10^{-4} |
| hsa-let-7d      | -8.30E-01        | 2.10x10^{-4} |
| hsa-miR-20b     | -8.28E-01        | 4.43x10^{-4} |
| hsa-miR-660     | -8.26E-01        | 4.15x10^{-4} |
| hsa-miR-376c    | -8.16E-01        | 1.65x10^{-3} |
| hsa-miR-192,\(^{-}\) | -7.74E-01        | 1.99x10^{-4} |
| hsa-miR-377     | -7.67E-01        | 3.60x10^{-4} |
| hsa-miR-18b     | -7.67E-01        | 6.73x10^{-4} |
| hsa-miR-29c\(^{-}\) | -7.66E-01        | 1.21x10^{-3} |
| hsa-miR-375     | -7.66E-01        | 6.19x10^{-4} |
| hsa-miR-148b    | -7.63E-01        | 5.17x10^{-4} |
| hsa-miR-127-3p  | -7.62E-01        | 1.64x10^{-3} |
| hsa-miR-136\(^{-}\) | -7.59E-01        | 5.34x10^{-4} |
| hsa-miR-200c    | -7.59E-01        | 1.93x10^{-4} |
| hsa-miR-342-3p  | -7.45E-01        | 5.11x10^{-3} |
| hsa-miR-923     | -7.31E-01        | 8.61x10^{-4} |
| hsa-miR-151a-5p | -7.30E-01        | 7.01x10^{-4} |
| hsa-miR-191     | -7.27E-01        | 1.06x10^{-3} |
| hsa-miR-450a    | -7.14E-01        | 1.15x10^{-3} |
| hsa-miR-131a-3p | -7.13E-01        | 8.95x10^{-4} |
| hsa-miR-454     | -6.99E-01        | 3.24x10^{-3} |
| hsa-miR-141     | -6.97E-01        | 4.59x10^{-3} |
| hsa-let-7f-1\(^{-}\) | -6.89E-01        | 2.58x10^{-3} |
| hsa-miR-204     | -6.87E-01        | 2.84x10^{-4} |
| hsa-miR-128     | -6.71E-01        | 3.74x10^{-3} |
| hsa-miR-30a\(^{-}\) | -6.59E-01        | 4.98x10^{-3} |
| hsa-miR-92b     | -6.46E-01        | 8.45x10^{-3} |
| hsa-miR-103     | -6.30E-01        | 6.62x10^{-4} |
| hsa-miR-582-5p  | -6.26E-01        | 2.76x10^{-3} |
| hsa-miR-455-5p  | -6.23E-01        | 3.55x10^{-3} |
| hsa-miR-519e\(^{-}\) | -6.13E-01        | 3.10x10^{-4} |
| hsa-miR-99a     | -6.12E-01        | 7.53x10^{-3} |
| hsa-miR-22      | -6.05E-01        | 2.12x10^{-3} |
| hsa-miR-122\(^{-}\) | -5.79E-01        | 5.61x10^{-3} |
| hsa-miR-99b     | -5.73E-01        | 1.43x10^{-3} |
| hsa-miR-552     | -5.53E-01        | 5.33x10^{-3} |
| hsa-miR-219-1-3p | -4.92E-01        | 3.57x10^{-3} |
| hsa-miR-548a-3p | -3.93E-01        | 7.99x10^{-3} |
| hsa-miR-491-5p  | -3.52E-01        | 4.61x10^{-3} |

hsa, Homo sapiens; miR/miRNA, microRNA.
Table IV. Top 15 GO terms of differentially expressed microRNA target genes.

| GO ID       | GO term                                                      | Count | P-value     | False discovery rate |
|-------------|--------------------------------------------------------------|-------|-------------|----------------------|
| **Biological process**                                                                                     |       |             |                      |
| GO:0000278  | Mitotic cell cycle                                          | 25    | 5.14x10^-21| 4.38x10^-18          |
| GO:0001301  | Cell division                                               | 20    | 1.17x10^-15| 4.99x10^-13          |
| GO:0006260  | DNA replication                                             | 14    | 5.92x10^-13| 1.68x10^-10          |
| GO:0000082  | G1/S transition of mitotic cell cycle                       | 13    | 5.73x10^-12| 1.22x10^-9           |
| GO:0007067  | Mitosis                                                     | 13    | 1.42x10^-10| 2.42x10^-8           |
| GO:0000075  | Cell cycle checkpoint                                       | 11    | 5.14x10^-10| 7.29x10^-8           |
| GO:0007049  | Cell cycle                                                 | 16    | 1.16x10^-8 | 1.42x10^-6           |
| GO:0000086  | G2/M transition of mitotic cell cycle protein kinase activity| 9     | 3.69x10^-8 | 3.93x10^-6           |
| GO:0000079  | Regulation of cyclin-dependent                              | 7     | 4.26x10^-8 | 4.03x10^-6           |
| GO:0000077  | DNA damage checkpoint                                       | 5     | 4.59x10^-7 | 3.91x10^-5           |
| GO:0000236  | Mitotic prometaphase                                        | 7     | 8.88x10^-7 | 6.31x10^-5           |
| GO:0031100  | Organ regeneration                                          | 6     | 8.27x10^-7 | 6.41x10^-5           |
| GO:0000087  | M phase of mitotic cell cycle                               | 7     | 1.89x10^-6 | 1.24x10^-4           |
| GO:0051726  | Regulation of cell cycle                                    | 6     | 3.35x10^-6 | 2.04x10^-4           |
| GO:0000083  | Regulation of transcription involved in G1/S phase of mitotic cell cycle | 4     | 5.85x10^-6 | 3.32x10^-4           |
| **Cellular component**                                                                                     |       |             |                      |
| GO:0005634  | Nucleus                                                     | 99    | 4.92x10^-27| 1.02x10^-24          |
| GO:0005737  | Cytoplasm                                                   | 96    | 7.53x10^-26| 7.79x10^-24          |
| GO:0005829  | Cytosol                                                     | 51    | 1.68x10^-17| 1.60x10^-15          |
| GO:0005654  | Nucleoplasm                                                 | 32    | 6.06x10^-16| 3.14x10^-14          |
| GO:0005730  | Nucleolus                                                   | 30    | 5.18x10^-9 | 2.14x10^-7           |
| GO:0005813  | Centrosome                                                  | 14    | 1.28x10^-8 | 4.41x10^-7           |
| GO:0000785  | Chromatin                                                   | 8     | 1.87x10^-8 | 5.53x10^-7           |
| GO:0005694  | Chromosome                                                  | 11    | 7.36x10^-7 | 1.90x10^-5           |
| GO:0005856  | Cytoskeleton                                                | 19    | 1.10x10^-6 | 2.28x10^-5           |
| GO:0000776  | Kinetochore                                                 | 6     | 1.03x10^-6 | 2.38x10^-5           |
| GO:0000775  | Chromosome, centromeric region                              | 6     | 1.57x10^-6 | 2.96x10^-5           |
| GO:0000794  | Condensed nuclear chromosome                                | 4     | 2.38x10^-5 | 4.10x10^-4           |
| GO:0000777  | Condensed chromosome kinetochore                            | 5     | 3.49x10^-5 | 5.56x10^-4           |
| GO:0048471  | Perinuclear region of cytoplasm                            | 11    | 5.25x10^-5 | 7.76x10^-4           |
| GO:0000922  | Spindle pole                                                | 5     | 9.46x10^-5 | 1.31x10^-3           |
| **Molecular function**                                                                                    |       |             |                      |
| GO:0005515  | Protein binding                                             | 100   | 6.85x10^-35| 2.18x10^-32          |
| GO:0000166  | Nucleotide binding                                          | 41    | 3.15x10^-11| 5.00x10^-9           |
| GO:0003677  | DNA binding                                                 | 31    | 1.26x10^-7 | 1.34x10^-5           |
| GO:0005524  | Adenosine triphosphate binding                              | 26    | 1.32x10^-6 | 1.05x10^-4           |
| GO:0019899  | Enzyme binding                                              | 9     | 2.50x10^-6 | 1.59x10^-4           |
| GO:0019904  | Protein domain specific binding                              | 8     | 6.99x10^-6 | 3.70x10^-4           |
| GO:0016301  | Kinase activity                                             | 9     | 1.10x10^-5 | 5.01x10^-4           |
| GO:0019901  | Protein kinase binding                                      | 8     | 1.05x10^-4 | 4.19x10^-3           |
| GO:0043425  | Basic helix-loop-helix transcription factor binding          | 3     | 1.39x10^-4 | 4.93x10^-3           |
| GO:0042393  | Histone binding                                             | 4     | 3.25x10^-4 | 1.03x10^-2           |
| GO:0003700  | Sequence-specific DNA binding transcription factor activity  | 15    | 4.07x10^-4 | 1.08x10^-2           |
| GO:0042826  | Histone deacetylase binding                                 | 4     | 4.00x10^-4 | 1.16x10^-2           |
| GO:0051082  | Unfolded protein binding                                    | 5     | 8.39x10^-4 | 2.05x10^-2           |
| GO:0008565  | Protein transporter activity                                 | 4     | 9.22x10^-4 | 2.09x10^-2           |
| GO:0008139  | Nuclear localization sequence binding                       | 2     | 1.28x10^-3 | 2.54x10^-2           |

GO, gene ontology.
Table V. KEGG pathways of differentially expressed microRNA target genes.

| KEGG ID  | KEGG term                                    | Count | False discovery rate |
|----------|----------------------------------------------|-------|----------------------|
| hsa04110 | Cell cycle                                   | 15    | 1.47x10^{-13}        |
| hsa05222 | Small cell lung cancer                       | 6     | 7.27x10^{-4}         |
| hsa04115 | Tumor protein 53 signaling pathway           | 5     | 2.13x10^{-3}         |
| hsa00240 | Pyrimidine metabolism                        | 5     | 7.56x10^{-3}         |
| hsa04114 | Oocyte meiosis                               | 5     | 1.31x10^{-2}         |
| hsa00072 | Synthesis and degradation of ketone bodies   | 2     | 1.85x10^{-2}         |
| hsa03030 | DNA replication                              | 3     | 2.05x10^{-2}         |
| hsa05215 | Prostate cancer                              | 4     | 2.15x10^{-2}         |
| hsa03013 | RNA transport                                | 5     | 2.25x10^{-2}         |
| hsa05162 | Measles                                      | 5     | 2.32x10^{-2}         |
| hsa04914 | Progesterone-mediated oocyte maturation      | 4     | 2.42x10^{-2}         |
| hsa05200 | Pathways in cancer                           | 7     | 3.61x10^{-2}         |

KEGG, Kyoto Encyclopedia of Genes and Genomes; hsa, Homo sapiens.

Figure 1. Regulatory network between miRNAs and target genes in liver cirrhosis tissues. The diamonds and ellipses represent the miRNAs and targets, respectively. The pink and green colors represent the relative upregulation and downregulation, respectively. miR/miRNA, microRNA; hsa, Homo sapiens.

Figure 2. Reverse transcription-quantitative polymerase chain reaction validation of microRNAs and targets in 5 pairs of blood samples from patients with liver cirrhosis and healthy volunteers. *P<0.01. LC, liver cirrhosis; CON, control; hsa, Homo sapiens; miR, microRNA; KIAA1524, cancerous inhibitor of protein phosphatase 2A.
mice demonstrated that E2F1-deficiency may largely inhibit the development of biliary liver fibrosis (48). In the present study, the dysregulation of LIFR, KIAA1524 and E2F1 in the cirrhotic liver clearly suggested their importance in the development of liver cirrhosis. The results of the function enrichment analysis of the target genes indicated that the cell cycle was the most significantly enriched pathway. This result is consistent with the importance of the cell cycle in various types of cancer (49).

In conclusion, a set of 48 differentially expressed miRNAs and 1,773 DEGs were identified in liver cirrhosis tissues compared with normal tissues. A total of 240 miRNA-target gene pairs whose expression was inversely correlated were identified. Additionally, a global miRNAs-target regulatory network was constructed, which was expected to improve the understanding of the regulatory mechanisms of liver cirrhosis pathology, and to provide a clearer biomarker for diagnosis and safer therapeutic strategies of liver cirrhosis. Additional functional studies are required to confirm the regulatory associations between the miRNAs and their predictive targets.

References

1. Schuppen D and Afdhal NH: Liver cirrhosis. Lancet 371: 838-851, 2008.
2. Siddique I, El-Naga HA, Madda JP, Memon A and Hasan F: Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 38: 427-432, 2003.
3. Bedossa P, Dargere D and Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449-1457, 2003.
4. Regev A, Berho M, Jeffers LJ, Milikowski C, Molteni E, Pyrsopoulos NT, Feng ZZ, Reddy KR and Schiff ER: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618, 2002.
5. Katsi V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Bedossa P, Dargere D and Paradis V: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906, 2005.
6. Pozero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Dienes HP and Odenthal M: Liver fibrosis: A dynamic and potentially reversible process. Histol Histopathol 25: 1075-1091, 2010.
7. Pinzani M and Vizzutti F: Fibrosis and cirrhosis reversibility: Clinical features and implications. Clin Liver Dis 12: 901-913, x, 2008.
8. Gieling RG, Burt AD and Mann DA: Fibrosis and cirrhosis reversibility-molecular mechanisms. Clin Liver Dis 12: 915-937, x, 2008.
9. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
10. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O′Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
12. Ellimova N, Schlattian M, Sowa JP, Dienes HP, Canbay A and Odenthal M: Circulating microRNAs: Promising candidates serving as novel biomarkers of acute hepatitis. Front Physiol 3: 476, 2012.
13. Wang XS, Heegaard NH and Orum H: MicroRNAs in liver disease. Gastroenterology 142: 1431-1443, 2012.
14. Borel K, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56: 1371-1383, 2012.
15. Giordano S and Columbano A: MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 57: 840-847, 2013.
16. Varnholt H, Drebbel U, Schulze F, Wedemeyer I, Schirrmer P, Dienes HP and Odenthal M: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223-1232, 2008.
17. Gupta A, Swaminathan G, Martin-Garcia J and Navas-Martín S: MicroRNAs, hepatitis C virus and HCV/HIV-1 co-infection: New insights in pathogenesis and therapy. Viruses 4: 2485-2513, 2012.
18. Landford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kaupsininen S and Orum H: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201, 2010.
19. Janssen HL, Ressink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, et al: Treatment of HCV infection by targeting microRNA-122. N Engl J Med 368: 1685-1694, 2013.
20. Noetel A, Kwiecinski M, Elfimova N, Huang J and Odenthal M: microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol 3: 49, 2012.
21. Wong CM, Wong CC, Lee JM, Fan DN, Au SL, and Ng IO: Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 55: 1453-1461, 2012.
22. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashovsky M, Marshall KA, Philadelphia KM, Sherman PM, Holko M, et al: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res 41 (Database Issue): D991-D995, 2013.
23. Law CW, Chen Y, Shi W and Smyth GK: Voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15: R29, 2014.
24. Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27: 431-432, 2011.
25. Huang DW, Sherman BT, Tan Q, Collins JR, Alvor DG, Royo I, Stephens R, Baseler MW, Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183, 2007.
26. Young MD, Wakefield MJ, Smyth GK and Oshlack A: Gene ontology analysis for RNA-seq: Accounting for selection bias. Genome Biol 11: R14, 2010.
27. Kanelisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
28. Visone R and Croce CM: miRNAs and cancer. Am J Pathol 174: 1131-1139, 2009.
29. Mirnezami AH, Pickard K, Zhang L, Primrose JN and Packham G: MicroRNAs: Key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 35: 339-347, 2009.
30. Ajit SK: Circulating microRNA signatures in the diagnosis and lethal risk stratification of acute coronary syndromes. Nucleic Acids Res 12: 3393-3399, 2012.
31. Bala S and Szabo G: MicroRNA signature in alcoholic liver disease. Int J Hepatol 2012: 492832, 2012.
32. Li L, Guo Z, Wang J, Yao G and Qiao Q: Serum miR-18a: A potential marker for hepatitis B virus-related hepatocellular carcinoma. Dig Dis Sci 57: 2910-2916, 2012.
33. Brockhausen J, Tay SS, Grzelak CA, Bertolino P, Bowen DG, d′Adiguido WM, Teoh N, Sok S, Shackel NK, Gamble JR, et al: miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int 35: 240-253, 2015.
34. Zhao J, Tang N, Wu K, Dai W, Ye C, Shi J, Zhang J, Ning B, Zeng X and Lin Y: miR-21 simultaneously regulates ERK1 and ERK2 in HaCaT cells. J Cell Physiol 231: 2739-2748, 2016.
35. Gupta A, Swaminathan G, Martin-Garcia J and Navas-Martin S: MicroRNAs, hepatitis C virus and HCV/HIV-1 co-infection: New insights in pathogenesis and therapy. Viruses 4: 2485-2513, 2012.
36. Wang XW, Heegaard NH and Orum H: MicroRNAs in liver disease. Gastroenterology 142: 1431-1443, 2012.
37. Borel K, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56: 1371-1383, 2012.
39. Niu J, Shi Y, Tan G, Yang CH, Fan M, Pfeffer LM and Wu ZH: DNA damage induces NF-xB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J Biol Chem 287: 21783-21795, 2012.

40. Bakirtzi K, Hatzipostolou M, Karagiannides I, Polytarchou C, Jaeger S, Iliopoulos D and Pothoulakis C: Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology 141: 1749-1761 e1, 2011.

41. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T and Shimotohno K: The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 6: e16081, 2011.

42. Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO and Wong CM: MicroRNA-142-3p and microRNA-142-5p are down-regulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. Front Med 9: 331-343, 2015.

43. Wang B, Li W, Guo K, Xiao Y, Wang Y and Fan J: miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 421: 4-8, 2012.

44. Znoyko I, Sohara N, Spicer SS, Trojanowska M and Reuben A: Expression of oncostatin M and its receptors in normal and cirrhotic human liver. J Hepatol 43: 893-900, 2005.

45. Yu HC, Chen HJ, Chang YL, Liu CY, Shiu CW, Cheng AL and Chen KF: Inhibition of CIP2A induces erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol 85: 356-366, 2013.

46. Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiu CW and Chen KF: Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis 5: e1359, 2014.

47. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et al: CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62, 2007.

48. Zhang Y, Xu N, Xu J, Kong B, Coppel B, Guo GL and Wang L: E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network. Hepatology 60: 919-930, 2014.

49. Światkowska A, Żydowicz P, Sroka J and Ciesiolka J: The role of the S' terminal region of p53 mRNA in the p53 gene expression. Acta Biochim Pol 63: 645-651, 2016.

50. Yildiz G, Arslan-Ergul A, Bagislar S, Konu O, Yuzugullu H, Gursoy-Yuzugullu O, Ozturk N, Ozen C, Ozdag H, Erdal E, et al: Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One 8: e64016, 2013.

51. Archer KJ, Mas VR, David K, Maluf DG, Bornstein K and Fisher RA: Identifying genes for establishing a multigenic test for hepatocellular carcinoma surveillance in hepatitis C virus-positive cirrhotic patients. Cancer Epidemiol Biomarkers Prev 18: 2929-2932, 2009.

52. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McVey P and Fisher R: Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 15: 85-94, 2009.

53. Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, Goria O, Hiron M, Daveau M and Salier JP: Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol 15: 300-309, 2009.

54. Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciąg M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L, Niewinski G, et al: Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. Int J Cell Biol 53: 208-217, 2014.

55. Vuppalanchi R, Liang T, Goswami CP, Nalamasu R, Li L, Jones D, Wei R, Liu W, Sarasani V, Janga SC and Chalasani N: Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One 8: e74471, 2013.